Resistance to mupirocin: No indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 19, Issue 4, 1999, Pages 313-314

  Vas, Stephen I ^a   Conly, John ^b   Bargman, Joanne M ^a   Oreopoulos, Dimitrios G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; PSEUDOMONIC ACID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CATHETER INFECTION; CLINICAL TRIAL; EDITORIAL; HUMAN; OINTMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0033453268     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900405     Document Type: Editorial

References (11)

1. Piraino B. A review of Staphylococcus aureus exit-site and tunnel infections in peritoneal dialysis patients. Am J Kidney Dis 1990; 16:89-95.
2. Shelton DM. A comparison of the effects of two antiseptic agents on Staphylococcus epidermidis colony forming units at the peritoneal dialysis catheter exit site. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin, 1991; 7: 120-4.
3. Wilson AP, Lewis C, O'Sullivan H, Shetty N, Neild GH, Mansell M. The use of povidone iodine in exit site care for patients undergoing continuous peritoneal dialysis (CAPD). J Hosp Infect 1997; 35:287-93.
4. Zimmerman SW, Ahrens E, Johnson CA, Craig W, Legget J, O'Brien M, et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 1991; 18:225-31.
5. Boyce JM. Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hosp Epidemiol 1996; 17:775-9.
6. Perez-Fontan M, Garcia-Falcon T, Rosales M, Rodriguez-Carmona A, Adeva M, Rodriguez-Lozano I, et al. Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: long term results. Am J Kidney Dis 1993; 22:708-12.
7. Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996; 7:2403-8.
8. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27:695-700.
9. Thodis E, Bhaskaran S, Pasadakis P, Bargman JM, Vas SI, Oreopoulos DG. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 1998; 18:261-70.
10. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17:811-13.
11. Fong SK, Dedier H, Izatt S, Vas S, Oreopoulos DG, Campbell E, et al. The lack of colonization of methicillin resistant S. aureus, mupirocin resistant S. aureus and vancomycin intermediate resistant S. aureus in a chronic ambulatory dialysis population. Can J Infect Dis 1998; 9(Suppl D):32D.